Cargando…
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
BACKGROUND: Absorption of current rapid-acting insulins is too slow for patients with diabetes mellitus to achieve optimal postprandial glucose control. Faster-acting insulin aspart (faster aspart) is insulin aspart in a new formulation with faster early absorption. We compared the pharmacokinetic/p...
Autores principales: | Heise, Tim, Stender-Petersen, Kirstine, Hövelmann, Ulrike, Jacobsen, Jacob Bonde, Nosek, Leszek, Zijlstra, Eric, Haahr, Hanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425492/ https://www.ncbi.nlm.nih.gov/pubmed/27878566 http://dx.doi.org/10.1007/s40262-016-0473-5 |
Ejemplares similares
-
A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016) -
Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015) -
Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009) -
Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016) -
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)